Fully human IgG1κ anti-CD20 monoclonal antibody for relapsing multiple sclerosis; binds a membrane‑proximal CD20 epitope on B cells, inducing B‑cell depletion via complement‑dependent cytotoxicity and Fc‑mediated ADCC/ADCP, reducing pathogenic antigen presentation and proinflammatory cytokine signaling; administered subcutaneously.
Fully human anti-CD20 IgG1κ monoclonal antibody that binds a membrane-proximal CD20 epitope on B cells and depletes them via complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP, thereby reducing pathogenic B-cell antigen presentation and proinflammatory cytokine signaling.
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP, leading to direct lysis and clearance of CD20+ cells.
A first-in-human Claudin 18.2–targeted antibody-drug conjugate; a monoclonal antibody binds CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload causing Topo‑I inhibition, DNA damage, and tumor cell death; administered every 3 weeks.
Monoclonal antibody targets CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload via linker cleavage, leading to Topo-I inhibition, DNA damage, and tumor cell death.
ADC binds CLDN18.2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload after linker cleavage, causing DNA damage and apoptotic cell death.
Anti-CD73 monoclonal antibody–drug conjugate administered IV; blocks CD73-mediated adenosine production and delivers the cytotoxic payload SN38 to CD73-expressing cells, inducing DNA damage via topoisomerase I inhibition.
Anti-CD73 monoclonal antibody–drug conjugate that binds and inhibits CD73 (ecto-5′-nucleotidase), reducing extracellular adenosine and associated A2A/A2B receptor–mediated immunosuppression, while delivering the topoisomerase I–inhibiting payload SN38 to CD73-expressing cells to induce DNA damage and apoptosis.
The anti-CD73 ADC binds CD73 on target cells, is internalized, and releases SN38 (a topoisomerase I inhibitor) that induces DNA damage and apoptosis in CD73-expressing cells.
Chimeric IgG1 anti-EGFR monoclonal antibody that binds EGFR (ErbB1), inhibits downstream signaling (MAPK/PI3K), and can mediate ADCC; administered at 75 mg in this study.
Chimeric IgG1 monoclonal antibody that binds the extracellular domain of EGFR (ErbB1), blocking ligand binding and receptor dimerization to inhibit downstream MAPK/PI3K signaling and tumor cell proliferation; can also mediate ADCC.
Cetuximab binds EGFR on target cells and engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and can activate complement), resulting in killing of EGFR+ cells; EGFR blockade is mainly cytostatic.
An anti-CD30 antibody–drug conjugate that delivers MMAE to CD30-positive Hodgkin/Reed–Sternberg cells, causing microtubule disruption and apoptosis.
Anti-CD30 monoclonal antibody conjugated via a protease-cleavable valine-citrulline linker to monomethyl auristatin E (MMAE). After binding CD30 on tumor cells and internalization, the linker is cleaved to release MMAE, which binds tubulin and inhibits microtubule polymerization, leading to G2/M arrest and apoptosis; the linker is plasma-stable, enhancing selectivity for CD30-positive cells.
The ADC binds CD30, is internalized, and releases MMAE via protease cleavage; MMAE disrupts microtubules (tubulin polymerization), causing G2/M arrest and apoptosis of CD30-positive cells.